https://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-english-415-articulo-long-term-treatment-persistence-maintained-reduction-S2529912323000700
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab...
AimsLimited data exist on low-density lipoprotein-cholesterol (LDL-C) level variability or
long term treatment
https://www.nice.org.uk/guidance/ta394
Overview | Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | Guidance...
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults
overviewevolocumabtreatingprimaryhypercholesterolaemia
https://www.acc.org/About-ACC/Press-Releases/2017/03/16/22/25/Fri-9am-Evolocumab-Significantly-Reduces-Risk-of-Cardiovascular-Events
Evolocumab Significantly Reduces Risk of Cardiovascular Events - American College of Cardiology
reduces riskcardiovascular eventsamerican collegeevolocumabsignificantly
https://www.acc.org/Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap
Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF - American...
https://www.mdpi.com/2077-0383/10/11/2504
The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular...
Elevated low-density lipoprotein (LDL) cholesterol is one of the leading causes of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9...
the effectpcsk9 inhibitor
https://www.acc.org/latest-in-cardiology/articles/2026/05/01/01/journal-wrap
Journal Wrap | Evolocumab Cuts Risk in Absence of ASCVD: Sotatercept For CpCPH, HFpEF - American...
https://www.acc.org/latest-in-cardiology/articles/2025/11/03/16/19/sat-1010am-vesalius-aha-2025
VESALIUS-CV: Evolocumab vs. Placebo in Patients Without Previous MI or Stroke - American College of...
https://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2696-130X2023000300085&lng=en&nrm=iso
Efecto del tratamiento combinado de estatinas y evolocumab en pacientes con enfermedad arterial...
https://www.aafp.org/pubs/afp/issues/2023/1000/poems-cholesterol-reducer.html
Cholesterol-Reducer Evolocumab Associated With a Nonsignificant Increase in Cardiovascular...
cholesterol reducerassociated withevolocumabincreasecardiovascular
https://www.mayoclinic.org/drugs-supplements/evolocumab-subcutaneous-route/description/drg-20152627
Evolocumab (subcutaneous route) - Side effects & dosage - Mayo Clinic
subcutaneous routeside effectsevolocumabdosagemayo
https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2020/08/28/16/09/HAUSER-RCT
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia Patients - American College of...
Anthony A. Bavry, M.D., M.P.H., FACC
familial hypercholesterolemiaamerican collegeevolocumabpediatricheterozygous
https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2013/12/16/11/38/Efficacy-and-Safety-of-Longer-Term-Administration
Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With...
efficacy and safety
https://www.amgen.com/newsroom/press-releases/2014/03/amgen-announces-positive-topline-results-from-phase-3-tesla-trial-of-evolocumab-amg-145-in-patients-with-homozygous-familial-hypercholesterolemia
Amgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In...
https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/12/17/15/00/FOURIER-Analysis
FOURIER Analysis Looks at Evolocumab and Risk of MACE Stratified by Obesity - American College of...
Evolocumab lowers MACE risk in obesity and ASCVD, with greatest benefit in class 2-3 obesity.
https://www.amgen.com/newsroom/press-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-rutherford2-trial-of-evolocumab-amg-145-in-patients-with-heterozygous-familial-hypercholesterolemia
Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145)...